Key Takeaways Medtronic's Q2 EPS of $1.36 and $8.96B in revenues beat estimates and grew year over year.MDT's Cardiovascular segment rose 9.3% organically, led by strong Cardiac Rhythm & Heart Failure sales.Medtronic raised its fiscal 2026 organic revenue and full-year adjusted EPS guidance.Medtronic plc (MDT) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.36, which rose 7.9% from the year-ago quarter’s figure and beat the Zacks Consensus Estimate by 3.82%.Without certain one-ti ...

Core Insights - Medtronic (MDT) is scheduled to announce its second-quarter fiscal 2026 results on November 18, with expectations of strong performance based on previous earnings surprises [1][2] Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Medtronic's revenues in the fiscal second quarter is $8.86 billion, indicating a 5.4% year-over-year increase [2] - The consensus estimate for EPS is projected to rise 4% to $1.31, with earnings estimates remaining unchanged over the past 60 days [2] Group 2: Segment Performance Cardiovascular - The Cardiovascular segment is expected to show strong momentum, with revenues projected to increase by 8.4% year over year, driven by the uptake of PulseSelect and Affera Sphere-9 systems [3][5] - The Evolut FX+ TAVR device is likely to gain traction in various markets, including Japan, benefiting from a competitor's exit [4] Neuroscience - Neuroscience revenues are anticipated to grow by 1.5% year over year, supported by strong sales in Cranial & Spinal Technologies and the adoption of AiBLE spine technology [6][8] - Neuromodulation performance is expected to benefit from U.S. growth in Pain Stim and the approval of the Altaviva device for treating urge urinary incontinence [7] Medical Surgical - Medtronic's Medical Surgical segment is projected to see a 5.4% year-over-year revenue increase, driven by demand for LigaSure technology and growth in the Advanced Energy product line [10][11] Diabetes - The Diabetes unit is expected to experience a 9.2% year-over-year revenue growth, fueled by the MiniMed 780G and Simplera Sync sensors [9][14] - Key FDA approvals during the quarter, including the SmartGuard algorithm and MiniMed 780G for type 2 diabetes, are likely to contribute to revenue growth [13][14] Group 3: Earnings Expectations - Medtronic currently holds a Zacks Rank of 3 (Hold) with an Earnings ESP of 0.00%, indicating a neutral outlook for beating estimates [15]

Core Insights - Medtronic plc (MDT) has received FDA approval for the Altaviva device, a minimally invasive implantable tibial neuromodulation therapy aimed at treating urge urinary incontinence, marking a significant advancement in bladder control therapies [1][9] - The introduction of the Altaviva device positions MDT as the only company with a comprehensive portfolio of neuromodulation therapies for bladder control symptoms, which is expected to enhance revenue growth and improve stock performance [3][4] Company Developments - The Altaviva device features a 15-year battery life, quick recharging capabilities, and is MRI-compatible, making it a patient-friendly option for those suffering from urge urinary incontinence [6][9] - Medtronic's market capitalization stands at $121.80 billion, with a projected revenue growth of 6.8% for fiscal 2026 compared to fiscal 2025 [4] - The company has consistently outperformed earnings expectations in the past four quarters, with an average surprise of 2.20% [4] Industry Context - Bladder control issues affect approximately 43 million U.S. adults, with nearly 16 million experiencing urge urinary incontinence, indicating a substantial market for the Altaviva device [10] - The global urinary incontinence therapeutics market is expected to grow at a CAGR of 4.0% from 2024 to 2030, driven by an aging population and increased awareness [10]